Who is sponsoring NCT03699969?

NCT03699969 is sponsored by Cairo University.

What drugs are being tested in NCT03699969?

Interventions in NCT03699969: Hypofractionated dose escalated VMAT.

What condition does NCT03699969 study?

NCT03699969 studies Locally Advanced Head and Neck Cancer.

Is NCT03699969 still recruiting?

NCT03699969 is currently status unknown. Last updated 11 October 2018.

Last reviewed 2018-10-11 · How we verify

NCT03699969

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing Hypofractionated Dose Escalated VMAT to Conventional CCRT in Locally Advanced Head and Neck Cancer

Status unknown NA Last updated 11 October 2018

What this trial tests

NA trial testing Hypofractionated dose escalated VMAT in Locally Advanced Head and Neck Cancer in 63 participants. Status unknown.

Timeline

1 January 2016

Primary endpoint
1 October 2018

15 October 2018

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	1 January 2016
Primary completion	1 October 2018
Estimated completion	15 October 2018

Drugs / interventions tested

Hypofractionated dose escalated VMAT

Conditions studied

Locally Advanced Head and Neck Cancer — all drugs for Locally Advanced Head and Neck Cancer →

Sponsor

Cairo University

Who can join

Adults 18 to 70, any sex, with Locally Advanced Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare efficacy and toxicity between hypofractionated dose escalated VMAT versus conventional concurrent chemoradiation in locally advanced head and neck cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Locally Advanced Head and Neck Cancer

Currently open trials in the same condition.

NCT06940180 — Toripalimab With Chemotherapy for Sinus Cancer · Phase 2 · recruiting

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03699969 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 11 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03699969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing